Amazon Bio Discovery launched to accelerate AI-powered drug discovery

Amazon Web Services (AWS) has introduced Amazon Bio Discovery, a new platform designed to harness AI in the field of drug discovery. The initiative aims to address the challenges of lengthy and expensive drug development processes by providing researchers with tools to streamline and enhance their work.

The platform offers a range of AI models, both open-source and commercial, specifically tailored for life sciences applications. These models can be customised using existing experimental data, enabling researchers to refine predictions and improve accuracy in areas such as antibody design. Early collaborations, including work with Memorial Sloan Kettering Cancer Center (MSK), have highlighted the platform’s potential to accelerate the design of new antibodies, a critical step in developing treatments for various diseases.

Rajiv Chopra, VP of AWS Healthcare AI and Life Sciences, commented in a statement from AWS, “AI agents make powerful scientific capabilities accessible to all drug researchers, not just those with computational expertise. These AI systems can help scientists design drug molecules, coordinate testing, learn from results, and get smarter with each experiment. This combination of cutting-edge AI and the robust, secure infrastructure AWS has built for regulated industries allows scientists to accelerate antibody discovery in ways that weren’t possible before.”

Amazon Bio Discovery also facilitates integration with physical laboratory partners, allowing researchers to test computational predictions in experimental settings. This connection between digital modelling and laboratory validation is intended to make the drug discovery process more efficient and reduce the likelihood of setbacks during clinical trials.

Nai-Kong Cheung, MD, PhD, Enid A Haupt Chair in Paediatric Oncology at MSK stated in the same statement from AWS: “We’re glad to be able to join forces with Amazon Bio Discovery to develop the next generation of antibodies that will potentially speed up the process to help patients worldwide. As researchers, we spent 20 years just to prove that the first generation of antibody worked, and then we spent another 13 years getting it into the human form before getting FDA approval. This path has been very inefficient. Patients come here with a clock. We need results sooner.”

The launch of this platform reflects a growing trend in the pharmaceutical and biotechnology sectors to adopt AI-driven approaches. By combining computational biochemistry with generative AI, researchers are increasingly able to tackle complex problems with greater speed and precision. Amazon Bio Discovery is positioned as part of this broader movement, aiming to support scientists in overcoming some of the most significant hurdles in drug development.

While the platform is still in its early stages, its introduction signals a shift towards more widespread use of AI in life sciences, with the potential to transform how new treatments are discovered and developed.

Source:

AWS launches Amazon Bio Discovery to accelerate AI-powered research in life sciences [Accessed April 15, 2026] https://www.aboutamazon.com/news/aws/aws-amazon-bio-discovery-ai-drug-research